Results 11 to 20 of about 17,826,638 (304)

Ofatumumab – a valid treatment option for chronic lymphocytic leukemia patients [PDF]

Therapeutics and Clinical Risk Management, 2017
Salma M AlDallal Haematology Laboratory, Amiri Hospital, Kuwait City, Kuwait Abstract: Ofatumumab Arzerra® is a human monoclonal antibody, which induces killing of a panel of tumor B-cell lines and primary tumor cells by the activation of in vitro ...
AlDallal SM
doaj   +2 more sources

Expressió de ZAP-70 en linfòcits B normals i síndromes limfoproliferatives B [PDF]

, 2006
[cat] La Leucèmia Limfàtica Crònica (LLC), la més freqüent de les leucèmies en el món occidental, és una malaltia produïda per la proliferació i cúmul de limfòcits B madurs, actualment incurable.
Crespo Maull, Marta
core   +6 more sources

Expression of COBLL1 encoding novel ROR1 binding partner is robust predictor of survival in chronic lymphocytic leukemia

Haematologica, 2018
Chronic lymphocytic leukemia is a disease with up-regulated expression of the transmembrane tyrosine-protein kinase ROR1, a member of the Wnt/planar cell polarity pathway. In this study, we identified COBLL1 as a novel interaction partner of ROR1. COBLL1
Hana Plešingerová, Pavlína Janovská, Archana Mishra, Lucie Smyčková, Lucie Poppová, Antonín Libra, Karla Plevová, Petra Ovesná, Lenka Radová, Michael Doubek, Šárka Pavlová, Šárka Pospíšilová, Vítězslav Bryja   +12 more
doaj   +1 more source

Highly similar genomic landscapes in monoclonal B-cell lymphocytosis and ultra-stable chronic lymphocytic leukemia with low frequency of driver mutations

Haematologica, 2018
Despite the recent discovery of recurrent driver mutations in chronic lymphocytic leukemia, the genetic factors involved in disease onset remain largely unknown.
Andreas Agathangelidis, Viktor Ljungström, Lydia Scarfò, Claudia Fazi, Maria Gounari, Tatjana Pandzic, Lesley-Ann Sutton, Kostas Stamatopoulos, Giovanni Tonon, Richard Rosenquist, Paolo Ghia   +10 more
doaj   +1 more source

Dysregulation of autophagy in chronic lymphocytic leukemia with the small-molecule Sirtuin inhibitor Tenovin-6 [PDF]

, 2013
The authors acknowledge TENOVUS Tayside for funding the studyTenovin-6 (Tnv-6) is a bioactive small molecule with anti-neoplastic activity. Inhibition of the Sirtuin class of protein deacetylases with activation of p53 function is associated with the pro-
Coates, Philip J., Groves, M.J., Prescott, A.R., Nicolaou, A., Murray, Karen, Ganley, Ian G.; id_orcid, Lain, S., Tauro, S., Haydock, S., Appleyard, V., Ganley, I.G., James, John, Nicolaou, Anna; id_orcid, Cunningham, Joan, Cunningham, J., Tauro, Sudhir, Murray, K., Prescott, Alan R., Drbal, Abed Alnaser A.A., Coates, P.J., James, J., MacCallum, S., Lain, Sonia, Drbal, A.A., MacCallum, Stephanie F., Drbal, Abed A., Haydock, Sally, Westwood, N.J., Prescott, Alan R.; id_orcid, Ganley, Ian G., Groves, Michael J., Nicolaou, Anna, Westwood, Nicholas J., Appleyard, Virginia, Prescott, AR, Murray, K, Nicolaou, A, Haydock, S, Drbal, AA, Cunningham, J, Appleyard, V, James, J, MacCallum, SF, Groves, MJ   +43 more
core   +1 more source

SLP76 integrates into the B-cell receptor signaling cascade in chronic lymphocytic leukemia cells and is associated with an aggressive disease course

Haematologica, 2016
I In the last decade, the B-cell receptor has emerged as a pivotal stimulus in the pathogenesis of chronic lymphocytic leukemia, and a very feasible therapeutic target in this disease.
Nili Dezorella, Ben-Zion Katz, Mika Shapiro, Aaron Polliack, Chava Perry, Yair Herishanu   +5 more
doaj   +1 more source

B cell receptor signaling in chronic lymphocytic leukemia [PDF]

Trends in Immunology, 2013
B cell receptor (BCR) signaling plays an important pathogenic role in chronic lymphocytic leukemia (CLL) and B cell lymphomas, based on structural restrictions of the BCR, and BCR-dependent survival and growth of the malignant B cells. In CLL and lymphoma subtypes, ligand-independent ('tonic') and ligand-dependent BCR signaling have been characterized,
Jan A, Burger, Nicholas, Chiorazzi
openaire   +2 more sources

Elevated risk of chronic lymphocytic leukemia and other indolent non-Hodgkin’s lymphomas among relatives of patients with chronic lymphocytic leukemia

Haematologica, 2009
Background Previous studies have shown increased familial risk for chronic lymphocytic leukemia. In the most comprehensive study to date, we evaluated risk of chronic lymphocytic leukemia and lymphoproliferative disorders among first-degree relatives of ...
Lynn R. Goldin, Magnus Björkholm, Sigurdur Y. Kristinsson, Ingemar Turesson, Ola Landgren   +4 more
doaj   +1 more source

Chronic lymphocytic leukaemia: Up-dated recommendations on diagnosis and treatment [PDF]

, 2004
Diagnosis and treatment of chronic lymphatic leukaemia (CLL) are currently undergoing great change. New knowledge of prognosis factors and the numerous new therapeutic procedures now available, such as purine analogues, high-dose treatment and monoclonal
Hallek, M., Emmerich, B., Bergmann, M.
core   +1 more source

Coexistence of chronic myeloid leukemia and diffuse large B-cell lymphoma with antecedent chronic lymphocytic leukemia: a case report and review of the literature

Journal of Medical Case Reports, 2018
Background Chronic lymphocytic leukemia and chronic myeloid leukemia are the most common types of adult leukemia. However, it is rare for the same patient to suffer from both.
Khadega A. Abuelgasim, Hinna Rehan, Maha Alsubaie, Nasser Al Atwi, Mohammed Al Balwi, Saeed Alshieban, Areej Almughairi   +6 more
doaj   +1 more source